Patents by Inventor Sylvia Richard-Bildstein

Sylvia Richard-Bildstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11839613
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: December 12, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Patent number: 11712438
    Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: August 1, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Publication number: 20230174514
    Abstract: The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 8, 2023
    Inventors: Oliver ALLEMANN, Eva CAROFF, Alexia CHAVANTON-ARPEL, Andrew CROXFORD, Francis HUBLER, Loïc JACOB, Emmanuel MEYER, Sylvia RICHARD-BILDSTEIN
  • Publication number: 20230165859
    Abstract: The present invention relates to derivatives of formula (I) wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.
    Type: Application
    Filed: November 27, 2022
    Publication date: June 1, 2023
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN
  • Patent number: 11446298
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: September 20, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Publication number: 20220175775
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: December 13, 2021
    Publication date: June 9, 2022
    Applicant: Idorsia Pharmaceuticals Ltd
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN, Lorenza WYDER PETERS, Davide POZZI, Olivier CORMINBOEUF
  • Patent number: 11325899
    Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: May 10, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
  • Patent number: 11306078
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2, and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: April 19, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Philippe Guerry, Francois Lehembre, Julien Pothier, Laetitia Pouzol, Sylvia Richard-Bildstein, Shuguang Yuan
  • Patent number: 11241431
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 8, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Isabelle Lyothier, Julien Pothier, Sylvia Richard-Bildstein, Thierry Sifferlen, Lorenza Wyder Peters, Davide Pozzi, Olivier Corminboeuf
  • Publication number: 20210395238
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Application
    Filed: September 3, 2021
    Publication date: December 23, 2021
    Applicant: ACTELTION PHARMACEUTICALS LTD
    Inventors: Hamed AISSAOUI, Martin BOLLI, Christoph BOSS, Sylvia RICHARD-BILDSTEIN, Patrick SIEBER
  • Patent number: 11136317
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: October 5, 2021
    Assignee: Actelion Pharmaceuticals LTD
    Inventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
  • Publication number: 20210113559
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 22, 2021
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Publication number: 20210115031
    Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 22, 2021
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Publication number: 20200385373
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2, and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: July 14, 2020
    Publication date: December 10, 2020
    Inventors: Hamed AISSAOUI, Philippe GUERRY, Francois LEHEMBRE, Julien POTHIER, Laetitia POUZOL, Sylvia RICHARD-BILDSTEIN, Shuguang YUAN
  • Publication number: 20200289507
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 17, 2020
    Applicant: Idorsia Pharmaceuticals Ltd
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN, Lorenza WYDER PETERS, Davide POZZI, Olivier CORMINBOEUF
  • Patent number: 10752620
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2 and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: August 25, 2020
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Philippe Guerry, Francois Lehembre, Julien Pothier, Laetitia Pouzol, Sylvia Richard-Bildstein, Shuguang Yuan
  • Publication number: 20200179383
    Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)a, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: June 11, 2020
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Publication number: 20200165235
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
  • Publication number: 20200108068
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 9, 2020
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • Patent number: 10584118
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: March 10, 2020
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber